Better Therapeutics (BTTX)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Oct 30, 2024 12:56 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Better Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | NA |
Cost Of Goods | NA | 0 | 0 | 0 | NA |
Gross Profit | NA | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 38 | 31 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -38 | -31 | 0 | 0 |
Non-Operating Income | NA | 0 | -10 | 0 | NA |
Interest Expense | NA | 1 | 0 | 0 | NA |
Pretax Income | NA | -40 | -40 | 0 | NA |
Income Taxes | NA | 0 | 0 | 0 | NA |
Minority Interest | NA | 0 | 0 | 0 | NA |
Investment Gains/Losses | NA | 0 | 0 | 0 | NA |
Other Income/Charges | NA | 0 | 0 | 0 | NA |
Income From Cont. Operations | NA | -40 | -40 | 0 | NA |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | NA |
Net Income (GAAP) | NA | -40 | -40 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -36 | -29 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | NA | 3 | 2 | 0 | NA |
Income After Depreciation & Amortization | 0 | -38 | -31 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 23.56 | 12.98 | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | -1.69 | -3.11 | NA | NA |
Diluted Net EPS (GAAP) | NA | -1.69 | -3.11 | NA | NA |
Fiscal Year end for Better Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | 0.00 |
Cost Of Goods | NA | NA | NA | NA | 0.00 |
Gross Profit | NA | NA | NA | NA | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 5.34 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -5.34 |
Non-Operating Income | NA | NA | NA | NA | 0.00 |
Interest Expense | NA | NA | NA | NA | 0.52 |
Pretax Income | NA | NA | NA | NA | -5.86 |
Income Taxes | NA | NA | NA | NA | 0.00 |
Minority Interest | NA | NA | NA | NA | 0.00 |
Investment Gains/Losses | NA | NA | NA | NA | 0.00 |
Other Income/Charges | NA | NA | NA | NA | 0.00 |
Income From Cont. Operations | NA | NA | NA | NA | -5.86 |
Extras & Discontinued Operations | NA | NA | NA | NA | 0.00 |
Net Income (GAAP) | NA | NA | NA | NA | -5.86 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | 38.50 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | -0.15 |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | -0.15 |